Amylyx Pharmaceuticals (AMLX)
(Delayed Data from NSDQ)
$13.31 USD
+0.06 (0.45%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $13.32 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AMLX 13.31 +0.06(0.45%)
Will AMLX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AMLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMLX
Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
AMLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock?
Other News for AMLX
AMLX makes New 52 Week Closing High on September 19
New 52 Week Closing High appears for AMLX after 3.76% move
New 52 Week Closing High appears for AMLX after 6.77% move
New 52 Week Closing High appears for AMLX after 0.93% move
Goldman Sachs Raises Price Target for AMLX to $20, Maintains Buy Rating | AMLX Stock News